Nov 04, 2021 / 08:30PM GMT
Unidentified Analyst -
Hi, everybody, and thank you for joining us in the end of earnings day to actually participate in this conference call with Stephane Bancel, the CEO of Moderna. We'll try to cover 4 topics today a little bit by the logic of durability of the business of COVID-19 vaccines, the challenge of multivalent vaccines, curing additional diseases beyond immunogenicity, and a little bit about the experience of being a CEO of the company that attempts to change the world by -- while growing up at the same time. So Stephane, thank you very much for joining us today.
Stephane Bancel - Moderna, Inc. - CEO & Director
Thank you for having me.
Questions and Answers:
Unidentified Analyst -So let's start with a discussion of the logic of boosting long term. So I think at this point, we kind of realize there is a logic to boost people once after getting the 2 initial shots. The question is the logic and evidence for the need for boosting every year.
There seems to be some debate that we will be building